German demand for drug VAT cut

12 November 2007

A total of 15 drug industry and pharmacy associations and organizations linked to health care in Germany are backing the demand by the technical sector health fund (TK) for a reduction in the rate of value-added tax on medicines. The demand - in the so-called Dusseldorf Declaration - is for a reduction from a current 19% to 7%. Medical bodies and patient associations are among those supporting the call.

The pharmacy federation, ABDA, says that a moderate reduction in VAT would free the health care system from a financial burden of 2.5 billion euros ($3.6 billion) a year and allow the public-sector health funds to cut their rates at least 0.2% a year. The declaration says that whether France, Italy or Poland is considered, the VAT rates almost everywhere are lower than in Germany, where veterinary drugs are taxed lower than those for humans.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight